Alloy Alternatives: Best Options for Every Menopause and HRT Use Case

What Alloy Does and Where It Falls Short

Alloy provides asynchronous telehealth consultations for menopause symptoms, prescribing a small set of FDA-approved hormones shipped directly to patients. The platform fills a real need: the 2022 NAMS position statement confirms that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause [5]. Alloy makes accessing these treatments faster than traditional scheduling workflows.

The limitations become clear quickly. Alloy does not bill insurance, so patients pay full cash price for both consultations and medications. The formulary is narrow. Women needing testosterone for hypoactive sexual desire, compounded formulations, combination estrogen-bazedoxifene (Duavee), or newer non-hormonal options like fezolinetant (Veozah) will not find them on the platform [6]. Alloy also does not manage complex cases involving a history of breast cancer, thrombophilia, or concurrent endocrine disorders. For these patients, a broader-scope alternative is necessary.

The platform does not appear to offer lab work coordination either. Baseline labs (lipid panel, metabolic panel, thyroid function) are recommended by AACE before initiating HRT in women over 45 [7]. Without integrated lab ordering, patients must coordinate this independently.

Alternative 1: HealthRX (Best for Comprehensive Hormone Optimization)

HealthRX pairs each patient with a board-certified physician who manages the full hormone picture, not just menopause symptoms. The formulary spans estradiol (transdermal and oral), micronized progesterone, testosterone cream, DHEA, thyroid support, and GLP-1 receptor agonists when metabolic symptoms overlap with perimenopause.

This matters clinically. The Global Consensus Statement on Menopausal Hormone Therapy (2013, endorsed by NAMS, IMS, EMAS, and four other societies) established that HRT should be individualized by symptom profile, risk factors, and patient preference [8]. A platform with a wider formulary and physician-led oversight can do this more effectively than one with a fixed product menu.

HealthRX also integrates lab ordering and monitoring. Checking serum estradiol, FSH, and SHBG levels before and 8 to 12 weeks after starting therapy aligns with Endocrine Society recommendations for optimizing dose titration [9]. Insurance billing and transparent pricing give patients more flexibility than cash-only models.

Alternative 2: Midi Health (Best for Dedicated Menopause Specialists)

Midi Health employs clinicians who specialize exclusively in menopause and midlife health. Consultations are synchronous (video), which gives patients real-time interaction with their provider. Midi accepts some insurance plans, reducing out-of-pocket cost relative to Alloy for eligible patients.

Midi prescribes FDA-approved systemic and local estrogen, progesterone, and (notably) testosterone, which Alloy does not. Testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women is supported by a 2019 global consensus position statement endorsed by the International Menopause Society, which found a significant improvement in satisfying sexual events with transdermal testosterone [10]. The Endocrine Society's 2019 guideline likewise supports short-term testosterone trial in postmenopausal women with HSDD after excluding other causes [9].

Midi's limitation is geography. It operates in a limited number of states, so availability depends on where you live. Response times can also be longer during high-demand periods compared to asynchronous models.

Alternative 3: Evernow (Best Budget Option for Straightforward Vasomotor Symptoms)

Evernow mirrors Alloy's asynchronous model but positions itself at a lower price point for core HRT. If your primary complaint is hot flashes and night sweats without complicating factors, Evernow may be the most cost-effective telehealth path to an estradiol prescription.

The evidence base for estradiol patches in vasomotor symptom relief is strong. A Cochrane systematic review of 24 RCTs (N=3,329) found that oral and transdermal estrogen reduced hot flash frequency by approximately 75% compared to placebo [11]. Both Alloy and Evernow prescribe from this same FDA-approved drug pool, so the clinical outcomes are comparable for uncomplicated cases.

Evernow shares Alloy's core weakness: limited scope. Complex perimenopause, surgical menopause, or patients needing non-hormonal alternatives like fezolinetant (a neurokinin-3 receptor antagonist FDA-approved in May 2023 for moderate-to-severe vasomotor symptoms [6]) are better served by platforms with broader prescribing capability.

Alternative 4: Winona (Best for Bioidentical Hormone Focus)

Winona emphasizes compounded bioidentical hormones alongside FDA-approved options. The platform prescribes estradiol, progesterone, DHEA, and testosterone, giving it a wider formulary than Alloy. Winona operates on a cash-pay subscription model.

A point of clarification: the FDA and the Endocrine Society note that FDA-approved "bioidentical" hormones (plant-derived, molecularly identical 17-beta estradiol and micronized progesterone) are distinct from compounded bioidentical hormone therapy (cBHT), which lacks FDA oversight for safety, efficacy, and consistency [12]. The NASEM 2020 report on cBHT found insufficient evidence that compounded preparations are safer or more effective than FDA-approved alternatives and recommended stronger FDA regulation [13].

Patients choosing Winona should confirm whether their prescribed formulation is FDA-approved or compounded, as this affects both safety data and insurance reimbursement eligibility.

Alternative 5: Local Menopause Specialist or NAMS-Certified Practitioner

For medically complex patients, no telehealth platform replaces an in-person menopause specialist. NAMS maintains a directory of NAMS-Certified Menopause Practitioners (NCMPs), clinicians who have passed a competency examination in menopause medicine [5].

This route is particularly important for women with a history of estrogen-receptor-positive breast cancer. The 2024 Endocrine Society clinical practice guideline on managing menopause symptoms in breast cancer survivors recommends against systemic hormone therapy in most cases and suggests alternatives including venlafaxine, gabapentin, cognitive behavioral therapy, and (where FDA-approved) fezolinetant [14]. These nuanced risk-benefit discussions require a specialist who can review imaging, pathology, and oncology records.

The downside is access. A 2023 survey published in Menopause found that only 20% of ob-gyn residency programs provided any menopause medicine training, contributing to a workforce shortage [15]. Wait times for NAMS-certified practitioners can stretch to months in underserved areas.

Comparing Non-Hormonal Options Across Platforms

Not every menopausal woman is a candidate for estrogen. Those with contraindications (active or recent VTE, certain hepatic conditions, undiagnosed vaginal bleeding) need non-hormonal alternatives [5]. The field changed meaningfully in 2023 with the FDA approval of fezolinetant (Veozah) 45 mg daily, the first neurokinin-3 receptor antagonist for vasomotor symptoms [6].

In the phase 3 SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced moderate-to-severe hot flash frequency by 61.3% at week 12 versus 42.4% for placebo [16]. Alloy does not prescribe fezolinetant. Platforms like HealthRX and Midi Health that offer a wider formulary can provide access to this option. Paroxetine 7.5 mg (Brisdelle), the only other FDA-approved non-hormonal vasomotor treatment, reduced hot flash frequency by about 33% in key trials [17].

SSRIs and SNRIs used off-label for hot flashes (venlafaxine 75 mg, escitalopram 10 to 20 mg) also have supporting evidence. A meta-analysis in JAMA Internal Medicine found that SSRIs/SNRIs reduced hot flash frequency by about 1.13 episodes per day compared to placebo [18].

Cost Comparison: Cash-Pay vs. Insurance-Billing Platforms

Alloy's cash-pay model typically runs $50 to $120 per month depending on which medications are prescribed. Generic transdermal estradiol patches through a GoodRx coupon or insurance can cost as little as $15 to $30 per month, and generic micronized progesterone (Prometrium equivalent) runs $10 to $25 per month at retail pharmacies [1].

The cost differential matters because HRT is often a long-term therapy. The 2022 NAMS position statement supports continuing HRT as long as benefits outweigh risks, with periodic reassessment, rather than imposing arbitrary duration limits [5]. Over five years, the difference between a $100/month cash-pay subscription and a $30/month insurance copay totals $4,200. Platforms that bill insurance (Midi Health, HealthRX, traditional clinics) can reduce this burden substantially for patients with pharmacy benefits.

The WHI follow-up data support long-term use in appropriate candidates. The 18-year cumulative follow-up of the WHI estrogen-alone trial (N=10,739) found no increase in all-cause mortality, cardiovascular mortality, or cancer mortality among women randomized to conjugated equine estrogen versus placebo [19].

How to Choose the Right Alternative

The decision depends on three variables: symptom complexity, insurance status, and formulary needs.

For uncomplicated vasomotor symptoms in a woman with no contraindications and no insurance, Alloy or Evernow provides the fastest path to an estradiol prescription. For women needing testosterone, DHEA, thyroid co-management, or metabolic support, HealthRX or Midi Health offer a more complete clinical framework. For women with breast cancer history, thrombophilia, or other high-risk profiles, a NAMS-certified in-person specialist is the standard of care.

The 2017 hormone therapy position statement from the Endocrine Society reinforces that route of administration matters: transdermal estradiol carries a lower venous thromboembolism risk than oral estrogen, a factor that should inform platform selection based on what each one prescribes [9]. Any platform that defaults to oral-only estrogen without discussing transdermal options is not following current evidence.

Labs at baseline and during follow-up are a quality marker. Serum estradiol levels between 40 and 100 pg/mL are generally targeted for symptom relief with transdermal therapy, per clinical practice patterns described in Endocrine Society guidance [9]. A platform that never orders labs cannot confirm whether dosing is adequate or excessive. Estradiol levels above 200 pg/mL on replacement doses warrant investigation for compliance issues or absorption variability [20].